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Abstract. 
 
BRCA1-associated RING domain 
(BARD1) was identified as a protein interacting with 
the breast cancer gene product BRCA1. The identifica-
tion of tumorigenic missense mutations within 
 
BRCA1
 
 
that impair the formation of BARD1ÐBRCA1 com-
plexes, and of 
 
BARD1
 
 mutations in breast carcinomas, 
sustain the view that 
 
BARD1
 
 is involved in 
 
BRCA1
 
-
mediated tumor suppression. We have cloned the mu-
rine 
 
Bard1
 
 gene and determined that its expression in 
different tissues correlates with the expression profile 
of 
 
Brca1
 
. To investigate the function of 
 
Bard1
 
, we have 
reduced 
 
Bard1
 
 gene expression in TAC-2 cells, a mu-
rine mammary epithelial cell line that retains morpho-
genetic properties characteristic of normal breast epi-
thelium. Partial repression of 
 
Bard1
 
, achieved by the 
transfection of TAC-2 cells with plasmids constitutively 
expressing ribozymes or antisense RNAs, resulted in 
marked phenotypic changes, consisting of altered cell 
shape, increased cell size, high frequency of multinucle-
ated cells, and aberrant cell cycle progression. Further-
more, 
 
Bard1
 
-repressed cell clones overcame contact in-
hibition of cell proliferation when grown in monolayer 
cultures and lost the capacity to form luminal structures 
in three-dimensional collagen gels. These results dem-
onstrate that 
 
Bard1 
 
repression induces complex 
changes in mammary epithelial cell properties which 
are suggestive of a premalignant phenotype.
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D
 
espite 
 
increasing information on the breast and
ovarian cancer susceptibility gene 1 (
 
BRCA1
 
),
 
1
 
our understanding of its role in the initiation and
progression of cancer remains limited. The predicted
amino acid sequence of 
 
BRCA1
 
 displays a RING finger
domain in the amino-terminal and a presumed transcrip-
tion activation domain in the carboxy-terminal region
(Miki et al., 1994). Nuclear localization (Scully et al.,
1997
 
a
 
) and copurification with RNA polymerase II (Scully
et al., 1997
 
b
 
) suggest a role for BRCA1 in transcriptional
regulation (Coene et al., 1997). The findings that the wild-
type allele is frequently lost in tumors from individuals
carrying 
 
BRCA1
 
 mutations (Kelsell et al., 1993), that
transfection of wild-type human 
 
BRCA1
 
 into breast and
ovarian cancer cells results in in vivo tumor suppression
(Shao et al., 1996), and that inhibition of 
 
BRCA1
 
 expres-
sion confers tumorigenic properties to NIH3T3 cells (Rao
et al., 1996), support the notion that 
 
BRCA1
 
 acts as a tu-
mor suppressor gene.
Although most of the mutations in 
 
BRCA1
 
,
 
 
 
identified
throughout the coding region, give rise to truncated pro-
teins, missense mutations have been described in the struc-
turally conserved cysteine residues within the RING fin-
ger of 
 
BRCA1
 
, indicating the functional relevance of this
domain (Castilla et al., 1994).
 
 
 
The RING finger domain
and its adjacent regions are essential for binding of
BRCA1 to BARD1 (BRCA1-associated ring domain),
which was discovered in a two-hybrid screen as a protein
that specifically interacts with BRCA1 (Wu et al., 1996).
 
BARD1
 
, like 
 
BRCA1
 
, encodes a RING finger protein ho-
mologous to 
 
BRCA1
 
 within the amino-terminal RING
and carboxy-terminal transcriptional transactivation do-
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main. The carboxy-terminal domains of 
 
BRCA1
 
 and
 
BARD1
 
 are homologous to a conserved domain present in
proteins with cell cycle checkpoint functions and desig-
nated BRCT domain (Koonin et al., 1996; Bork et al.,
1997). Overexpression of the complete 
 
BRCA1
 
 gene or
its BRCT domain in
 
 Saccharomyces cerevisiae
 
 inhibits
growth (Humphrey et al., 1997), supporting the notion
that the BRCT domain is involved in cell cycle control. In
keeping with this finding, in response to DNA damage,
BARD1 and BRCA1 colocalize with proliferating cell nu-
clear antigen (PCNA), a protein involved in DNA replica-
tion (Cox, 1997), and with Rad51 (Jin et al., 1997; Scully et
al., 1997
 
c
 
), a protein involved in eucaryotic double strand
break repair (Shinohara et al., 1992). This dynamic local-
ization is consistent with a role for 
 
BRCA1
 
 and 
 
BARD1
 
complexes in DNA replication checkpoint response, as
well as with recent reports indicating that BRCA1 is re-
quired for transcription-coupled repair of oxidative DNA
damage (Gowen et al., 1998).
Adding to the proposed function of 
 
BRCA1
 
, expression
studies have shown that the murine 
 
Brca1 
 
gene (Bennett
et al., 1995) is expressed in diverse tissues, notably in those
with a marked proliferative index including the breast tis-
sue during development and pregnancy (Hakem et al.,
1996; Rajan et al., 1997), a finding similar to that observed
for the human 
 
BRCA1
 
 gene (Lane et al., 1995).
Neither the function of 
 
BARD1
 
 during development
nor the mechanism and specific consequences of BARD1
interaction with the BRCA1 protein have been elucidated.
Recently, 
 
BARD1
 
 missense mutations, accompanied by
loss of the wild-type allele, have been identified in human
breast carcinoma (Thai et al., 1998), supporting the notion
that 
 
BARD1 
 
may
 
 
 
participate in 
 
BRCA1
 
 mediated tumor
suppression.
The objective of this study was to characterize the mu-
rine 
 
Bard1
 
 gene and to elucidate the functional properties
of 
 
Bard1
 
. In addition, by partially repressing 
 
Bard1 
 
in the
TAC-2 mammary gland epithelial cell line (Soriano et al.,
1995), we found that 
 
Bard1
 
 is required for S-phase pro-
gression, contact inhibition of growth, and formation of
organized, lumen-containing structures. Altogether, these
observations suggest a role of 
 
Bard1
 
 as tumor suppressor
along with 
 
Brca1
 
.
 
Materials and Methods
 
Cloning of the Murine Bard1 Gene
 
Murine 
 
Bard1
 
 sequences were amplified from total RNA extracted from
normal murine breast tissue with primers directed against the RING fin-
ger region and the BRCT domain of the human 
 
BARD1 
 
gene
 
 
 
(corre-
sponding to positions 268 and 1,914 of the human 
 
BARD1
 
 cDNA). The 5
 
9
 
end and 3
 
9 
 
end sequences of murine 
 
Bard1 
 
were cloned with the 5
 
9 
 
race
and the 3
 
9 
 
race method, respectively, using kits from Bio-Rad (Hercules,
CA). The murine 
 
Bard1
 
 cDNA was sequenced and is available under
GenBank/EMBL/DDBJ accession number AFO57157.
 
RNase Protection Assays
 
RNase protection experiments were carried out with probes against the
murine 
 
Bard1
 
 cDNA sequence, comprising nucleotides (nt) 1,575Ð1,916
or 1,865Ð2,145, against 
 
Atm
 
, comprising nt 8,494Ð8,668 of the murine 
 
Atm
 
cDNA sequence, and against p21 corresponding to nt 381Ð722 of the mu-
rine p21 cDNA. The corresponding cDNA regions were amplified by re-
verse transcription (RT)-PCR from total RNA from normal murine
breast tissue. Amplified fragments were cloned into pBSII-KS and anti-
sense probes were transcribed with either T3 or T7 polymerase. Total
RNA was extracted from different tissues or from different cell lines by
Trizol (GIBCO, Grand Island, NY) extraction, and 10 
 
m
 
g of total RNA
were incubated with antisense probes as described previously (Menoud
et al., 1996).
 
Cell Culture
 
TAC-2 cells (Soriano et al., 1995), a clonally derived subpopulation of the
NMuMG mammary gland epithelial cell line (CRL 1636; American Type
Culture Collection, Rockville, MD) (Owens et al., 1974), were cultured in
collagen-coated tissue culture flasks (Falcon, Becton Dickinson, San Jos,
CA) in high glucose DME (GIBCO, Basel, Switzerland) supplemented
with 10% fetal calf serum (FCS; GIBCO), penicillin (110 
 
m
 
g/ml) and
streptomycin (110 
 
m
 
g/ml).
 
Generation of Antisense and Ribozyme
Expression Clones
 
A 
 
Bard1
 
 antisense expression clone was generated by cloning the DNA
fragment comprising nt 789Ð1,773 of the murine 
 
Bard1
 
 sequence and Hind-
III and NotI restriction sites (derived from pBS bluescript vector) into the
HindIII and NotI sites of the PCDNA3 vector resulting in antisense orien-
tation in respect to the cytomegalovirus (CMV) promoter. The corre-
sponding sense construct was cloned into the EcoRI and XhoI sites. The
inserted sense sequence (5
 
9 
 
AGTAACTG
 
ATG
 
TCATTGTTCCTG
 
AT-
G
 
AGGAAGCGCAGGAGTACTCTGA . . . 3
 
9
 
) contains an open read-
ing frame (ORF) with translation initiation codons (
 
boldface
 
) followed by
stop codons (
 
underline
 
).
Single strand ribozyme sequences and complementary DNA sequences
were synthesized in vitro as oligomers containing two regions of 12 or 13
nucleotides complementary to the murine 
 
Bard1
 
 coding sequence inter-
rupted by the ribozyme loop. The two ribozyme target regions correspond
to nt 1,864Ð1,890 and nt 1,963Ð1,988, respectively. Single strand ribozymes
sequences were 5
 
9
 
-TCGAGCAGTAACTCATGTttcgtcctcacggactcatcag-
ATTGTTCCTGATGGGTAC-3
 
9
 
 and 5
 
9
 
-TCGAGGTGAAAGCCTGT-
ttcgtcctcacggactcatcagTGGACAGCAAAGGGTAC-3
 
9
 
 (
 
uppercase
 
, murine
 
Bard1
 
 sequences; 
 
lowercase
 
, ribozyme loop), respectively. Ribozymes and
their complementary DNA sequences were hybridized in vitro and were
designed with overlapping ends creating sites suitable for oriented cloning
into the KpnI and XhoI sites of the PCDNA3 vector.
 
Generation of Ribozyme and Antisense-expressing
Cell Lines
 
TAC-2 cells were transfected with ribozyme or antisense constructs by the
calcium phosphate transfection procedure and selected in neomycin (300
 
m
 
g/ml). Stable clonal cell lines were generated by limiting dilution and
subcultured in the presence of neomycin (300 
 
m
 
g/ml). 12 clonal cell lines
were established, which we designated AB-A to AB-L. Two different ri-
bozyme constructs were transfected and stable cell lines were generated
and designated RB-18 and RB-21, respectively. As a control, TAC-2 cells
were transfected with either PCDNA3 vector alone (PC3) or a 
 
Bard1
 
sense sequence (Bard1-sense) designed to abort protein translation after
translation initiation codons. The AB-I clone was established by Òdroplet
cloning,Ó a recently described limiting dilution procedure (Montesano et
al., 1998), whereas the AB-K clone was obtained by manually removing a
colony of defined morphology from a low cell density collagen gel culture,
followed by its enzymatic dissociation into single cells, as previously de-
scribed (Soriano et al., 1995; Montesano et al., 1998).
 
Western Blots
 
Synthetic peptides corresponding to amino acid residues 79Ð93, 101Ð114,
and 141Ð155 of Bard1, were used to generate polyclonal antibodies des-
ignated PVC, WFS, and MIQ, respectively, in rabbits. Antibodies were
affinity purified on peptide coupled Sepharose-CNBR (Pharmacia Bio-
tech, Piscataway, NJ). Anti-p21 antibodies were murine polyclonal anti-
bodies (Ab-9; NeoMarkers, Union City, CA) and were applied in a 1:50
dilution.
Protein extracts from TAC-2 cells expressing wild-type or repressed
Bard1 protein levels were prepared by harvesting cells from subconfluent
cultures. Cells were directly lysed in loading buffer and 100 
 
m
 
g of protein
per lane were loaded on 7.5% SDS-PAGE and blotted onto nylon filters. 
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Membranes were blocked with 10% milk powder in TBS. Antibody incu-
bation with purified anti-Bard1 (WFS) or preimmune serum was in a
1:100 dilution. Secondary anti-rabbit peroxidase-coupled antibodies were
applied in a 1:6,000 dilution. Signal detection was performed with the en-
hanced chemiluminescence kit (Amersham, Arlington Heights, IL).
 
FACS
 
¨ 
 
Analyses
 
To study cell cycle in subconfluent monolayer cultures, cells were seeded
at 4 
 
3 
 
10
 
4
 
 cells/ml in collagen-coated 35-mm Petri dishes and grown in
complete medium (DME, 10% FCS) for 24Ð36 h. Cells were harvested
with trypsin-EDTA, fixed with 70% ethanol, treated with RNase A (100
U/ml), and stained with propidium iodide (50 
 
m
 
g/
 
m
 
l). FACS
 
¨
 
 analyses
were performed on a FACScan
 
¨
 
 flow cytometer (Becton Dickinson, Ful-
lerton, CA).
To obtain synchronized cell cultures, cells were grown to form colonies
from 20Ð200 cells. Cultures were then rinsed with PBS and incubated with
serum-free medium for 36 h, at which time growth was reinduced by addi-
tion of complete medium. Cells were harvested at 4, 12, 18, 24, and 36 h af-
ter addition of complete medium, fixed in 70% ethanol, and then pro-
cessed for FACS
 
¨
 
 analysis as described above.
To study cell cycle in postconfluent cultures, cells were seeded at satu-
rating cell density (2 
 
3 
 
10
 
5
 
 cells/ml) in 16-mm wells and incubated at 37
 
8
 
C
for 2 d, at which time medium was aspirated and replaced with fresh me-
dium with or without the indicated treatment. Culture media and treat-
ments were renewed every 2 d. After 5 d, cells were harvested with
trypsin-EDTA, fixed in 70% ethanol, and processed for FACS
 
¨ 
 
analysis,
as described above. The mean percentage of cells in S-phase and G2/M
phase for each experimental condition were compared with controls using
StudentÕs unpaired 
 
t
 
 test.
Collagen Gel Cultures and Quantification of
Lumen Formation
Wild-type and transfected TAC-2 cell lines were harvested using trypsin-
EDTA, centrifuged, and then embedded in three-dimensional collagen
gels as described (Soriano et al., 1995). Media were changed every 2Ð3 d,
and the cultures were incubated at 378C for the times indicated.
To quantitatively assess lumen formation, TAC-2 cells were suspended
at 104 cells/ml in collagen gels (1.5 ml) cast into 35-mm dishes and incu-
bated with 1 mg/ml hydrocortisone and 10 mg/ml insulin. After 8 d, 150
randomly selected colonies per experimental condition were examined in
each of at least three separate experiments, using the 103 objective of a
Nikon Diaphot TMD inverted photomicroscope (Tokyo, Japan), and ar-
bitrarily classified as cysts when containing a clearly discernible lumen.
Values are expressed as mean percentage of cysts and compared with con-
trols using the StudentÕs unpaired t test.
Processing for Light and Electron Microscopy
Collagen gel cultures were fixed in situ overnight with 2.5% glutaralde-
hyde in 0.1 M sodium cacodylate buffer, pH 7.4. After extensive rinsing in
the same buffer, the collagen gels were cut into 3 3 3-mm fragments.
These were postfixed in 1% osmium tetroxide in veronal acetate buffer
for 45 min and processed as described (Montesano et al., 1991). Semithin
sections (1 mm) were cut with an LKB ultramicrotome, stained with 1%
methylene blue, and then photographed under transmitted light using an
Axiophot photomicroscope (Zeiss, Germany). Thin sections were stained
with uranyl acetate and lead citrate, and examined with a Philips EM 300
electron microscope (Eindhoven, The Netherlands).
Immunofluorescence
Cells were seeded on collagen-coated coverslips at 5 3 104 cells/ml and
grown for 25 h, at which time they were fixed in methanol for 5 min, fol-
lowed by acetone for 30 s. The coverslips were rinsed in PBS and stained
for indirect immunofluorescence with either polyclonal anti-Bard1 anti-
bodies (PVC, WFS, or MIQ) or polyclonal anti-p21 antibodies as de-
scribed (Irminger-Finger et al., 1996). Anti-Bard1 antibodies were applied
in a 1:100 dilution and anti-p21 antibodies in a 1:25 dilution. Rhodamine-
conjugated secondary anti-rabbit IgGs (Oncogene Research, Cambridge,
MA) were applied in a 1:200 dilution. Cells were incubated for DNA
counterstaining in SYTOX Green Stain (Molecular Probes, Eugene, OR)
for 15 min, mounted with PVA mounting medium (Sigma Chemical Co.,
St. Louis, MO), and then photographed with the 633 objective of a Zeiss
Axiophot photomicroscope.
Results
Characterization of Murine Bard1
We have searched for and cloned the murine Bard1 gene
by RT-PCR, with primers designed from the human
BARD1 sequence, on total RNA extracted from normal
adult murine breast tissue. Analysis of the murine Bard1
cDNA revealed an ORF coding for 774 amino acids,
highly homologous to the human BARD1. Comparison of
human and murine BARD1 protein sequences led to the
identification of three regions of high homology compris-
ing the amino-terminal RING finger (95% identity), the
ankyrin repeats (97% identity), and the BRCT domain
(91% identity). Interestingly, the ankyrin repeats repre-
sent an evolutionarily conserved region in addition to the
RING finger and the BRCT domain (Fig. 1). The homol-
ogy between the BARD1 sequences is strikingly higher
than the homologies observed between the BRCA1 pro-
tein sequences from different species. Whereas the short
RING finger regions (46 amino acids) of the different
BRCA1 genes are 100% identical, their BRCT domains
reveal 23% of nonconservative amino acid substitutions
between the human and mouse sequences. Overall, the
human and murine BARD1 sequences are more homolo-
gous than the human and murine BRCA1 sequences,
which suggests that Bard1 might be evolutionarily more
conserved that Brca1.
Figure 1. Comparison of deduced amino acid se-
quences of BARD1 and BRCA1. Mouse and hu-
man BARD1 and BRCA1 sequences were
aligned and percentages of homologies based on
identical positions were calculated. The RING
finger regions, the ankyrin repeats, and the
BRCT domains, are indicated.The Journal of Cell Biology, Volume 143, 1998 1332
Expression Pattern of Bard1
To determine the pattern of expression of Bard1 and its
correlation with Brca1 expression, we performed RNase
protection experiments. Bard1 expression was detected in
a large variety of tissues examined (thymus, liver, spleen,
lung, stomach, muscle, bone, and testis), a selection of
which is presented in Fig. 2 A. High expression levels were
found in testis and spleen. In most tissues Bard1 was found
to correlate with the expression of the Brca1 gene. How-
ever, when transcript levels of both genes were measured,
Brca1 levels exceeded Bard1 expression in most cases.
We next assessed the expression of Bard1 during devel-
opment and in hormonally regulated organs, namely the
mammary gland and the uterus. We found that during em-
bryogenesis Bard1 is transiently expressed from day 8 to
day 12, with a maximum expression at day 10 of embryo-
genesis, whereas the expression of Brca1 increases from
embryonic day 8 through 12 (Fig. 2, A and B). In the
ovary, as well as in the uterus and the mammary gland
from virgin and pregnant mice, Bard1 is coexpressed with
Brca1. However, Bard1 and Brca1 expression levels are
modulated differently in hormonally controlled tissues
during the ovulatory cycle. Specifically, in the uterus
Bard1 expression is increasing from diestrus through post-
estrus, whereas Brca1 expression increases from diestrus
to early estrus and decreases during estrus and postestrus
(Fig. 2, A and B).
These results suggest that the expression levels of Bard1
could modulate the abundance of Bard1ÐBrca1 complexes
during development and in hormonally regulated tissues.
Repression of Bard1 in Mammary Epithelial Cells
To obtain a functional in vitro model for the selective ab-
rogation of Bard1 gene expression, we used TAC-2 cells
(Soriano et al., 1995), a clonal population derived from the
NMuMG normal murine mammary gland epithelial cell
line (Owens et al., 1974). We initially determined that the
BARD1 homologue Bard1 was expressed in TAC-2 cells
by using RT-PCR on total RNA extracted from TAC-2
cells and by sequencing of the PCR products. We next
cloned Bard1 antisense or ribozyme (Burke, 1996) se-
quences into the PCDNA3 expression vector under the
transcriptional control of the CMV promoter, as described
in Materials and Methods. Antisense or ribozyme encod-
ing plasmids were stably transfected into TAC-2 cells.
To determine the level of target gene repression, RNase
protection experiments were performed on total RNA
extracted from the different transfected clonal cell lines.
Although nontransfected TAC-2 cells, mock-transfected
PC3, and Bard1-sense cells showed similar levels of Bard1
mRNA expression, TAC-2 cells transfected with either
Bard1-antisense or ribozyme constructs presented a signif-
icant repression of Bard1 mRNA levels (Fig. 3 A, panel a).
To assess the specificity of Bard1 repression in TAC-2
cells, total RNA from nontransfected, antisense-express-
ing, and ribozyme expressing cells was analyzed by RNase
protection using a cRNA for an unrelated gene, Atm. The
levels of Atm transcripts were not significantly altered in
any of the cell lines studied (Fig. 3 A, panel b). To deter-
mine whether Bard1 repression also affected the expres-
sion levels of genes involved in cell cycle regulation, we
tested the expression level of p21 by RNase protection
(Fig. 3 A, panel c). The concentration of p21 mRNA was
the same in nontransfected TAC-2 cells and in Bard1-anti-
sense expressing cells.
To evaluate the expression levels of the Bard1 protein in
the cell lines generated, we raised three different antibod-
ies (PVC, WFS, and MIQ) against peptides representing
distinct regions within the amino-terminal domain of Bard1,
as described in Materials and Methods. In cell extracts
from TAC-2 cells and mock-transfected PC3 cells, a pro-
tein migrating with a molecular weight of z95 kD could be
detected by Western blot analysis (Fig. 3 B, panel a),
which is slightly slower than the predicted molecular
weight of murine Bard1 (87 kD), but similar to the appar-
ent molecular weight of human BARD1 (Wu et al., 1996).
Bard1 protein levels were significantly reduced, albeit to a
different extent, in all Bard1-antisense and ribozyme-
expressing clones, when compared with mock-transfected
PC3 cells (Fig. 3 B, panel b). When equal amounts of total
protein extracts were analyzed, Bard1 protein expression
appeared to be reduced by 20Ð50% in antisense and ri-
bozyme-expressing cells.
To ascertain that Bard1 protein reduction was not due
to a general reduction of protein expression, we tested the
expression of p21. As described above, p21 RNA levels
were not reduced in Bard1-antisense expressing cells. Un-
like the Bard1 protein level, the p21 protein levels re-
Figure 2. Expression of Bard1 and Brca1 in different murine tis-
sues. (A) Ribonuclease protection assay of Bard1 and Brca1
mRNA. RNase protection was performed using Bard1 and Brca1
probes in simultaneous hybridization with 10 mg of yeast tRNA,
RNA from TAC-2 mammary epithelial cells, or with RNAs from
different murine tissues. (B) Quantification of RNase protection
assay. Bard1 and Brca1 signal intensities were measured and pre-
sented on a scale from 0 to 12 for each RNA. Numbers corre-
spond to RNA samples in A. Black bars, Bard1 expression; white
bars, Brca1 expression.Irminger-Finger et al. Bard1 Repression in Mammary Epithelial Cells 1333
mained unaltered in the Bard1 repressed cell lines (Fig. 3
B, panel b), supporting the conclusion that Bard1 protein
levels were specifically reduced.
Anti-Bard1 antibodies were also used in immunolocal-
ization studies on Bard1-antisense and ribozyme express-
ing cells. Although in TAC-2 cells or in mock-transfected
PC3 cells the Bard1 protein could be localized to the nu-
cleus, as reported for human BARD1 (Jin et al., 1997), the
intensity of the nuclear staining was reduced in most of the
antisense and ribozyme-expressing cell lines, as illustrated
for two representative cell lines AB-I and AB-K (Fig. 4
A). Similar results were obtained with three different poly-
clonal anti-Bard1 antibodies. To test the specificity of
Bard1 repression, we used anti-p21 antibodies and found
that the p21 nuclear signal was not reduced in the Bard1
antisense expressing cell lines. The intensity of the nuclear
p21 signal was similar in all stable cell lines (presented for
TAC-2, AB-I and AB-K cells in Fig. 4 B). Taken together,
these results demonstrate that ribozyme and antisense-
mediated repression of Bard1 leads to a specific decrease
of Bard1 mRNA levels and to a reduction of Bard1 pro-
tein levels.
Repression of Bard1 Induces Alterations of
Cellular Morphology
Transfection of Bard1-antisense or ribozyme constructs
led to characteristic phenotypic changes in stable transfec-
tants which were reproduced to varying degrees in 10 out
of 14 clonal cell lines. When compared with TAC-2 cells,
PC3 cells, or Bard1-sense cells, Bard1-repressed cells dis-
played a flat appearance and an increased cell size. The
nuclei of most cells were enlarged and up to 30% of the
cells contained multilobed or multiple nuclei, as confirmed
by 496-diamidino-2-phenylindole (DAPI) staining of nu-
clear DNA. A similar phenotype was observed for the ri-
bozyme-expressing cells and the clonal cell lines generated
from the antisense expressing cells. Among the transfec-
tants studied, the phenotypic changes were most pro-
nounced in AB-I and AB-K cells as illustrated in Fig. 5.
Repression of Bard1 Induces Retardation of S-phase
The finding that Bard1 repression in TAC-2 cells results in
multinucleation raised the question as to whether this
gene may be important for cell cycle functions. To test this
Figure 3. Bard1 expression in different Bard1-antisense and ribozyme expressing cell lines. (A) 10 mg of total RNA extracted from
TAC-2 cell lines were tested by RNase protection assays with probes against Bard1 and GAPDH (panel a) against Atm (panel b), and
against p21 (panel c). TAC-2, nontransfected cells; PC3, mock-transfected PC3; Bard1-sense, control transfected Bard1-sense cells; AB-
heterog, parental anti-Bard1 transfected cells; AB-H to AB-L, clonal cell lines derived from anti-Bard1; RB-18, ribozyme-transfected
cells. Arrows, antisense protected band of correct size, additional slower migrating bands were seen in some samples after longer expo-
sure. (B) Western blot analysis of protein levels in antisense and ribozyme expressing cells. Antibodies generated against the Bard1 pep-
tides PVC, WFS, and MIQ were tested on Western blots of protein extracts from TAC-2 cells and mock-transfected PC3 cells (PC3)
cells (panel a). Preimmune serum (P), corresponding to PVC antiserum, and purified PVC (1), WFS (2), and MIQ (3) antibodies were
probed in a 1:100 dilution. Protein extracts from mock-transfected TAC-2 cells (PC3), ribozyme-expressing cells (RB-18), and antisense
expressing cells (AB-H, AB-I, and AB-K) were blotted onto nitrocellulose filters and detected with PVC anti-Bard1 antibodies by
chemiluminescence (panel b).The Journal of Cell Biology, Volume 143, 1998 1334
hypothesis, we assessed the effect of Bard1 repression on
cell cycle progression by FACS¨ analysis. Asynchronous
cultures of nontransfected TAC-2 cells showed a typical
distribution of cell cycle phases, with roughly similar cell
events counted in G1 and G2/M, and less in S-phase (see
Fig. 6 A, left panel). In contrast, asynchronous cultures of
Bard1 antisense expressing cells exhibited an abnormal
cell cycle distribution, consisting of a significant increase
of G1 and a marked reduction of both S- and G2/M phases
(presented for AB-I and AB-K cells in Fig. 6 A, middle
and right panels). A similar distribution was observed in
the heterogeneously transfected cell population and in
eight different Bard1 repressed clonal cell lines (Table I).
These data suggest that repression of Bard1 in TAC-2 cells
induced a retardation of the cell cycle with a resulting ac-
cumulation of cells in G1 phase. To determine at which
cell cycle stage the delay occurred in Bard1 repressed cells,
we synchronized cultures of TAC-2 cells in G1 phase by
serum starvation, and performed FACS¨ analysis at differ-
ent time points after reinduction of growth, as described in
Materials and Methods. Readdition of serum to nontrans-
fected TAC-2 cells resulted in the rapid onset of cell cycle,
the normal pattern of cell cycle distribution being reached
8Ð16 h after induction of growth (Fig. 6, A and B, compare
left panels). Strikingly, however, the onset of the cell cycle
in Bard1 repressed AB-I cells was dramatically delayed.
Cells remained in G1-phase for the first 16 h after serum
readdition and slowly entered and progressed through
S-phase only after 22 h, resulting in the absence of G2/M
phase cells 36 h later (Fig. 6 B, middle panel). A similar, al-
beit less pronounced, delay was observed in AB-K cells,
which remained in G1-phase for 16 h, slowly progressed
through S-phase, and finally reached G2/M phase after 22 h
(Fig. 6 B, right panel). These results suggest that Bard1 is
required for S-phase progression.
An additional interesting feature of Bard1 repressed
cells was observed when the synchronized cell population
of individual cell lines was presented as DNA content
against cell size (Fig. 6 C). In nontransfected lines, the ma-
jority of cells are found in either G1 or G2/M. Most strik-
ingly, AB-K and AB-I cells did not form two distinct pop-
ulations corresponding to G1 and G2/M phase cells with a
distinct DNA content of 2N and 4N, respectively, as ob-
served with TAC-2 cells, but formed a diffuse population
of z4N. AB-I cells, in addition, contained another popula-
tion of cells with a DNA content of z8N. These results
correlate well with the morphological phenotype of AB-I
and AB-K cells, consisting of a large proportion of en-
Figure 4. Immunolocalization
of Bard1 and p21 in non-
transfected and in Bard1-
antisense expressing TAC-2
cells. (A) Anti-Bard1 staining
and DAPI staining in mock-
transfected PC3 cells and in
clonal cell lines AB-I and
AB-K is presented. Pictures
were taken with identical ex-
posure times for all cell lines,
and demonstrate reduced
Bard1 signal in AB-I and
AB-K cells. Bar, 10 mm. (B)
Anti-p21 staining and DAPI
staining was performed as de-
scribed for anti-Bard1. The
p21 antibody was used in a
1:25 dilution.Irminger-Finger et al. Bard1 Repression in Mammary Epithelial Cells 1335
larged and/or multilobed nuclei as illustrated in Fig. 5.
Taken together, these observations suggest that Bard1 re-
pression could lead to aneuplody and polyploidy.
Loss of Contact Inhibition in Bard1-repressed Cells
AB-K, and to a lesser extent AB-I cells, appeared to have
lost control of contact-induced growth inhibition when
reaching confluence. Although wild-type cells and mock-
transfected TAC-2 cells formed regular monolayers in
postconfluent cultures, AB-K cells manifested a tendency
to overlap each other and to grow in a disorganized criss-
cross pattern (data not shown). The differential behavior
of control and AB-K cells was particularly pronounced
when the cells were grown in the presence of exogenous
growth factors. Thus, the addition of either epidermal
growth factor (EGF) or insulin-like growth factor I (IGF-I)
did not induce multilayering in TAC-2 or PC3 cells, but re-
sulted in a marked degree of cell stratification in AB-K
cells (Fig. 7). To quantitatively characterize this observa-
tions, AB-K and mock-transfected PC3 cells were grown
to confluence and their proliferation rate was subse-
quently monitored by FACS¨ analysis with and without
the addition of either EGF or IGF-I. Whereas PC3 cells
had the same distribution of G1, S, and G2/M phase cells
in the presence or absence of exogenous growth factors,
AB-K cells progressed efficiently into S and G2/M phase
in the presence of either EGF or IGF-I (Fig. 8). This indi-
cates that AB-K cells have lost sensitivity to contact inhi-
bition of growth.
To determine whether AB-I or AB-K cells had become
tumorigenic, nude mice were injected with nontransfected
TAC-2 cells, AB-I, or AB-K cells (106 cells per mouse, six
mice for each cell line), and observed for 10 wk. Neither
TAC-2 cells nor AB-I or AB-K cells induced tumor for-
mation in the 18 mice injected. Experiments were repeated
with another group of 18 mice and observed for 10 wk with-
out detecting the appearance of tumors. These results are
consistent with the dependence of AB-K cells on the addi-
tion of growth factors for uncontrolled growth.
Repression of Bard1 Inhibits Lumen Formation by 
TAC-2 Cells
TAC-2 cells have the remarkable ability to mimic several
essential components of ductal or alveolar morphogenesis
when grown in collagen gels in the presence of either
hepatocyte growth factor (HGF) or hydrocortisone (Sori-
ano et al., 1995). We therefore assessed whether Bard1
could influence the morphogenetic properties of these
cells. When grown in collagen gels under control condi-
tions for 5Ð8 d, mock-transfected PC3 cells gave rise to
small colonies with a morphology ranging from irregular
cell aggregates to poorly branched structures. Addition of
HGF to the cultures induced the formation of highly ar-
borized branching cords, as previously observed with non-
transfected TAC-2 cells. Addition of HGF to collagen gel
cultures of Bard1 repressed AB-I or AB-K cells induced
branching tubulogenesis to a similar extent as in mock-
transfected cells (data not shown). These findings suggest
that Bard1 does not play a major role in the elongation
and branching of duct-like structures by TAC-2 cells.
We next analyzed whether Bard1 repression could influ-
ence lumen formation by TAC-2 cells. When grown in col-
lagen gels in the presence of hydrocortisone, mock-trans-
fected PC3 cells formed spheroidal cysts enclosing a
widely patent lumen (Fig. 9 A) delimited by a palisade of
cubic epithelial cells (Fig. 9 D), as previously observed
with nontransfected TAC-2 cells (Soriano et al., 1995). In
contrast, under the same experimental conditions, AB-I
cells formed solid aggregates devoid of lumen (Fig. 9, B
and E) and AB-K cells formed irregularly shaped cell ag-
Figure 5. Morphological phenotype of Bard1-antisense and ri-
bozyme expressing cells. Representative fields of untransfected
TAC-2 cells (A) and clonal antisense expressing AB-I (B) and
AB-K (C) cells. Whereas nontransfected TAC-2 cells have an ho-
mogeneous polygonal shape, AB-I and AB-K cells show in-
creased cytoplasmic and nuclear size and multinucleation. Bar,
100 mm.The Journal of Cell Biology, Volume 143, 1998 1336
gregates occasionally containing small focal lumina (Fig. 9,
C and F). A quantitative analysis demonstrated a marked
inhibition of lumen formation in Bard1 repressed cells, as
evidenced by a significant six- and eightfold (P 5 0.001)
decrease in the mean percentage of cysts formed by AB-I
and AB-K cells, respectively, when compared with PC3
cells (Fig. 10). Taken together, these results demonstrate
that the repression of Bard1 expression inhibits the forma-
tion of alveolar-like cystic structures by TAC-2 cells.
Discussion
The finding of constitutive BARD1 missense mutations in
breast cancer patients (Thai et al., 1998) and missense mu-
tations within the RING domain of BRCA1 that mediates
BARD1 binding activity,  has led to the proposal that
BARD1 plays a role in tumor suppression in conjunction
with BRCA1.
The simultaneous analysis of the expression levels of
Brca1 and Bard1 in a variety of tissues demonstrates a
similar expression profile in most tissues, consistent with
the hypothesis of their functional interaction. However, an
inversion of the stoichiometry of Brca1 and Bard1 RNA is
observed during the ovulatory cycle in the uterus and to a
lesser extent in the mammary gland. This finding suggests
a role for Bard1 as modulator of Brca1 functions in these
tissues.
It was therefore of interest to characterize the pheno-
type resulting from altered levels of Bard1 expression in
mammary gland epithelial cells. Our results provide cumu-
lative evidence that partial but specific repression of the
Bard1 gene can be achieved by antisense or ribozyme ex-
pression: firstly, the expression of antisense and ribozyme
constructs aimed at different regions of the Bard1 se-
quence results in the same phenotype in transiently trans-
fected cells and in several clonal cell lines; secondly, ex-
pression of sense constructs, or antisense sequences aimed
at an unrelated gene, Atm, did not result in the repression
of Bard1 RNA or protein, or in an altered morphological
phenotype (our unpublished observations). Interestingly,
the repression of Bard1 resulted in only limited repression
of Bard1 protein levels (20Ð50%). It is possible that com-
plete repression of Bard1 would be lethal to the cells, and
that selection pressure led to the establishment of Bard1
repressed cell lines with relatively mild reduction of Bard1
protein levels.
Bard1-repressed cells display a distinct phenotype con-
sisting of altered morphology and S-phase retardation.
Figure 6. FACS¨ analysis of
Bard1-repressed cells. (A)
Cell cycle distribution of
asynchronously growing
TAC-2 cells and Bard1-
repressed AB-I and AB-K
cells. Percentages indicate
the mean values of four
independent experiments.
(B) Cell cycle progression
of nontransfected and
Bard1-repressed TAC-2 cells
after G1 arrest. Cell cycle
distributions of synchro-
nized cells are shown for
each cell line 4, 8, 16, 22,
and 36 h after readdition of
serum. (C) Presentation of
DNA content versus cell
size in G1-arrested cells
grown for 16 h after readdi-
tion of serum. In nontrans-
fected cells, two different
populations with a distinct
DNA content (2N and 4N)
can be observed. In AB-K
cells, only the G1 cells form a distinct (2N) population, whereas cells presumed to be in G2/M exhibit a heterogeneous DNA con-
tent. In AB-I cells, a cell population with a DNA content of z8N is observed.
Table I. Cell Cycle Distribution of Nonsynchronized
Cell Cultures
Cell line
Percent of cells in cell cycle phase
G1 S G2/M
TAC-2 (6*) 33 39 28
PC3 (6) 34 38 28
AB-H (6) 40 35 25
AB-I (6) 56 19 25
AB-J (3) 42 32 26
AB-K (7) 56 21 23
AB-L (2) 44 32 24
RB18 (5) 50 19 31
RB24 (4) 60 18 22
*Number of experiments performed with individual cell lines to determine mean per-
centage. SEM were between 62 and 66.Irminger-Finger et al. Bard1 Repression in Mammary Epithelial Cells 1337
During S-phase, BARD1 has been shown to colocalize
with BRCA1 and PCNA (Jin et al., 1997; Scully et al.,
1997a,c). The steady-state levels of BARD1 remain con-
stant during cell cycle progression, in contrast to BRCA1
levels that reach a maximum during S-phase. Aggregation
of BARD1 molecules into BRCA1 nuclear dots occurs
during S-phase, suggesting that the recruitment of BARD1
depends on BRCA1 (Jin et al., 1997). Our results indicate
that Bard1 by itself is required for specific functions dur-
ing S-phase and that its repression leads to S-phase retar-
dation. Interestingly, morphological features of the Bard1
repressed cells, such as multinucleation and nuclear lobu-
lation, have also been observed as a consequence of alter-
ations in genes involved in cell cycle regulation, such as G1
cyclins or p21 (for review see Murray, 1994; Zavitk and
Zipursky, 1997), which suggests that the phenotype of
Bard1 repressed cells could be a consequence of aberrant
cell cycle progression.
The alterations in cell cycle progression of Bard1-
repressed cells could be indicative of an upregulation of
cell cycle inhibitors, such as p21. The upregulation of p21
was observed in tissues of Brca1-knockout mice (Hakem
et al., 1996). Further, BRCA1 itself has been demon-
strated as an activator of p21 transcription (Ouchi et al.,
1998; Zhang et al., 1998) either as coactivator of p53 or in
the absence of p53 (Somasundaram et al., 1997). As shown
in this paper, the expression of p21 was not upregulated in
Bard1 repressed cells, since mRNA and protein levels re-
mained unaltered in Bard1 antisense-expressing cells.
Therefore, the observed S-phase retardation in Bard1 re-
pressed cells must involve other pathways than p53-p21.
Since loss of normal tissue organization is one of the
first changes seen in the development of breast cancer, it
was relevant to assess whether Bard1 repression would af-
fect the morphogenetic properties of TAC-2 cells. When
grown in collagen gels in the presence of hydrocortisone,
Figure 7. Loss of contact in-
hibition in Bard1-repressed
cells. Cells were seeded in
collagen-coated 16-mm wells
at saturating cell density (2 3
105 cells/ml) and grown for
2 d, at which time the cul-
tures were incubated in the
absence or the presence of 20
ng/ml EGF for a further 5 d.
In EGF-supplemented cul-
tures, mock-transfected PC3
cells form a contact-inhibited
cobblestone-like monolayer
(a), whereas antisense ex-
pressing AB-K cells (b) grow
in a disordered crisscross pat-
tern. (c and d) Thin sections
perpendicular to the plane of
cultures shown in a and b
demonstrate the lack of strat-
ification in PC3 cells and the
obvious multilayering in
AB-K cells. Bars: (a and b)
100 mm; (c and d) 5 mm.
Figure 8. FACS¨ analysis of mock-transfected and Bard1-anti-
sense expressing cells grown to confluence. Mock-transfected
PC3 cells and Bard1-antisense expressing AB-K cells were grown
to confluence, incubated with or without addition of either EGF
(20 ng/ml) or IGF-I (50 ng/ml) for a further 5 d, and then sub-
sequently analyzed by FACS¨ as described in Materials and
Methods.The Journal of Cell Biology, Volume 143, 1998 1338
TAC-2 cells transfected with vector sequences only (PC3)
formed highly organized cystic structures, as previously de-
scribed for nontransfected TAC-2 cells (Soriano et al., 1995).
In contrast, two different clones of Bard1 antisense-trans-
fected cells (AB-I and AB-K) formed disorganized solid
aggregates devoid of a central lumen. Our findings there-
fore suggest that Bard1 regulates cellular activities in-
volved in the control of epithelial morphogenesis, and that
loss of this function leads to disruption of normal tissue ar-
chitecture. In this context, it is interesting that nontumori-
genic mammary epithelial cells grown in three-dimen-
sional matrices form acinar-like spherical structures with a
central lumen, whereas breast cancer cells lack this prop-
erty and form disorganized colonies (Petersen et al., 1992).
The failure of normal morphogenesis and altered re-
sponse to hydrocortisone in Bard1 repressed AB-I and
AB-K cells may conceivably result from changes in levels
or functions of molecules involved in cellÐcell adhesion or
the establishment and maintenance of cell polarity and
cellÐcell adhesion functions. Similar defects have been de-
scribed in a human mammary epithelial cell model and
shown to be functionally related to integrin expression lev-
els (Weaver et al., 1996, 1997).
Since it was proposed that BARD1 acts as a tumor sup-
pressor along with BRCA1 (Thai et al., 1998), it could
be expected that repression of Bard1 would induce a simi-
lar phenotype as BRCA1 repression. BRCA1 antisense-
expressing fibroblasts were reported to acquire a tumori-
genic potential (Rao et al., 1996). Bard1-repressed cells,
AB-I or AB-K, although insensitive to contact inhibition
of growth, when injected into nude mice were not tumori-
genic, indicating that Bard1 antisense expression gives rise
to a premalignant phenotype. It remains to established
whether the complete inhibition of Bard1 expression
could induce a different phenotype.
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